Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 Jul;28(7):1466-70.
doi: 10.1097/HJH.0b013e328339f20e.

Enhanced blood pressure and appetite responses to chronic central melanocortin-3/4 receptor blockade in dietary-induced obesity

Affiliations
Comparative Study

Enhanced blood pressure and appetite responses to chronic central melanocortin-3/4 receptor blockade in dietary-induced obesity

John H Dubinion et al. J Hypertens. 2010 Jul.

Abstract

Method: We examined the role of central nervous system (CNS) endogenous melanocortin 3/4 receptors (MC3/4R) activity in controlling cardiovascular and metabolic functions in Sprague Dawley rats fed a high-fat diet (n = 6) for 10 months compared with rats fed a standard chow (normal fat, n = 8) starting at 3 weeks of age.

Results: At 7 months of age, high-fat rats were heavier (473 +/- 3 vs. 424 +/- 7 g), consumed more calories with larger, less frequent meals and had reduced respiratory quotient (RQ) compared with normal-fat rats. After 10 months on the diets, arterial and venous catheters were implanted for measurement of mean arterial pressure (MAP) and heart rate (HR) 24-h/day and i.v. (intravenous) infusions, and a 21G steel cannula was placed in the lateral ventricle for intracerebroventricular (ICV) infusions. High-fat rats were heavier (528 +/- 14 vs. 477 +/- 11 g) with increased visceral adiposity and significantly higher MAP (108 +/- 3 vs. 102 +/- 1 mmHg). After a 5-day control period, the rats were infused with a MC3/4R antagonist (SHU-9119, 1 nmol/h, ICV) for 10 days followed by a 5-day recovery period. SHU-9119 infusion for 10 days increased caloric intake significantly more in high-fat rats (159 +/- 19 vs. 64 +/- 8 kcal). Despite increasing caloric intake and rapid weight gain, MC3/4R antagonism reduced MAP more in high-fat diet compared with normal-fat rats (-7.9 +/- 0.3 vs. -4.7 +/- 1.3 mmHg, average reduction of last 4 days of blockade).

Conclusion: These observations suggest that a high-fat diet increases endogenous activity of the CNS MC3/4R and that an intact MC3/4 appears to play an important role in linking increased blood pressure with diet-induced obesity.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: none

Figures

Figure 1
Figure 1
Effects of chronic ICV administration of the MC3/4R antagonist, SHU-9119 (1 nmol/hr) on caloric intake in SD rats fed a NF (n=8) or HF (n=6) diet for 10 months.
Figure 2
Figure 2
Effects of chronic ICV administration of the MC3/4R antagonist, SHU-9119 (1 nmol/hr), on (A) MAP, (B) change in MAP, and (C) HR in SD rats fed a NF (n=8) or HF (n=6) diet for 10 months.
Figure 2
Figure 2
Effects of chronic ICV administration of the MC3/4R antagonist, SHU-9119 (1 nmol/hr), on (A) MAP, (B) change in MAP, and (C) HR in SD rats fed a NF (n=8) or HF (n=6) diet for 10 months.

References

    1. Garrison RJ, Kannel WB, Stokes J, Castelli WP. Incidence and precursors of hypertension in young adults: The Framingham Offspring Study. Prev Med. 1987;16:235–251. - PubMed
    1. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41:625–633. - PubMed
    1. Haynes WG, Sivitz WI, Morgan DA, Walsh SA, Mark AL. Sympathetic and cardiorenal actions of leptin. Hypertension. 1997;30:619–623. - PubMed
    1. Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest. 1997;100:270–278. - PMC - PubMed
    1. Dunbar JC, Hu Y, Lu H. Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes. 1997;46:2040–2043. - PubMed

Publication types